Marker Therapeutics Stock Fundamentals
| MRKR Stock | USD 4.43 0.24 5.73% |
Marker Therapeutics fundamentals help investors to digest information that contributes to Marker Therapeutics' financial success or failures. It also enables traders to predict the movement of Marker Stock. The fundamental analysis module provides a way to measure Marker Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Marker Therapeutics stock.
At this time, Marker Therapeutics' Depreciation And Amortization is relatively stable compared to the past year. As of 04/24/2024, Total Revenue is likely to grow to about 3.5 M, while Selling General Administrative is likely to drop slightly above 5.6 M. Marker | Select Account or Indicator |
Marker Therapeutics Company Return On Asset Analysis
Marker Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Marker Therapeutics Return On Asset | -0.35 |
Most of Marker Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marker Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Marker Total Assets
Total Assets |
|
Based on the latest financial disclosure, Marker Therapeutics has a Return On Asset of -0.3536. This is 95.96% lower than that of the Biotechnology sector and 98.5% lower than that of the Health Care industry. The return on asset for all United States stocks is 152.57% higher than that of the company.
Marker Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Marker Therapeutics's current stock value. Our valuation model uses many indicators to compare Marker Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Marker Therapeutics competition to find correlations between indicators driving Marker Therapeutics's intrinsic value. More Info.Marker Therapeutics is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . At this time, Marker Therapeutics' Return On Equity is relatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Marker Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Marker Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Marker Therapeutics' earnings, one of the primary drivers of an investment's value.Marker Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marker Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marker Therapeutics could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics of similar companies.Marker Therapeutics is currently under evaluation in return on asset category among related companies.
Marker Fundamentals
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (2.49) % | ||||
| Operating Margin | (2.78) % | ||||
| Current Valuation | 22.19 M | ||||
| Shares Outstanding | 8.9 M | ||||
| Shares Owned By Insiders | 12.16 % | ||||
| Shares Owned By Institutions | 22.90 % | ||||
| Number Of Shares Shorted | 107.89 K | ||||
| Price To Earning | (9.39) X | ||||
| Price To Book | 2.73 X | ||||
| Price To Sales | 11.59 X | ||||
| Revenue | 3.31 M | ||||
| Gross Profit | (17.13 M) | ||||
| EBITDA | (14.58 M) | ||||
| Net Income | (14.05 M) | ||||
| Cash And Equivalents | 18.08 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 7.62 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | 1.58 X | ||||
| Cash Flow From Operations | (16.44 M) | ||||
| Short Ratio | 5.22 X | ||||
| Earnings Per Share | (1.59) X | ||||
| Target Price | 12.5 | ||||
| Beta | 1.54 | ||||
| Market Capitalization | 39.4 M | ||||
| Total Asset | 17.13 M | ||||
| Retained Earnings | (436.29 M) | ||||
| Working Capital | 14.05 M | ||||
| Current Asset | 6.85 M | ||||
| Current Liabilities | 5.93 M | ||||
| Net Asset | 17.13 M |
About Marker Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marker Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marker Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marker Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 2.9 M | 3 M | |
| Total Revenue | 3.3 M | 3.5 M | |
| Cost Of Revenue | 10.4 M | 15.1 M | |
| Stock Based Compensation To Revenue | 0.26 | 0.25 | |
| Sales General And Administrative To Revenue | 2.26 | 2.14 | |
| Research And Ddevelopement To Revenue | 3.15 | 2.99 | |
| Capex To Revenue | (0.63) | (0.66) | |
| Revenue Per Share | 0.38 | 0.25 | |
| Ebit Per Revenue | (4.40) | (4.62) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Marker Therapeutics Piotroski F Score and Marker Therapeutics Altman Z Score analysis. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Marker Stock analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Marker Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marker Therapeutics. If investors know Marker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marker Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.59) | Revenue Per Share 0.376 | Quarterly Revenue Growth 0.392 | Return On Assets (0.35) | Return On Equity (0.83) |
The market value of Marker Therapeutics is measured differently than its book value, which is the value of Marker that is recorded on the company's balance sheet. Investors also form their own opinion of Marker Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Marker Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marker Therapeutics' market value can be influenced by many factors that don't directly affect Marker Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marker Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marker Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marker Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.